Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM9S51)

Drug Name

ELND-002 Drug Info

Synonyms

ELND-002 (oral, multiple sclerosis); Alpha-4 integrin antagonists (oral, autoimmune diseases), Elan; Alpha-4 integrin antagonists (oral, multiple sclerosis), Elan; ELND-002 (oral, multiple sclerosis), Elan

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMM9S51

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-4 (ITGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vedolizmab	DMV3YMX	Crohn disease	DD70	Approved	[3]
Antegren	DMNC64R	Multiple sclerosis	8A40	Approved	[4]
Natalizumab	DMAK85L	Crohn disease	DD70	Approved	[5]
PB006	DMVHGLA	Crohn disease	DD70	Phase 3	[6]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[7]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[8]
Senktide	DMOH8LD	Epilepsy	8A60-8A68	Phase 2	[9]
BIO-1211	DMKICA3	Asthma	CA23	Phase 2	[10]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[8]
ELND-004	DMLQYVD	Autoimmune diabetes	5A10	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4 (ITGA4)	TT4BT06	ITA4_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01318421) A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis. U.S. National Institutes of Health.
2	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
3	Clinical pipeline report, company report or official report of Takeda (2009).
4	Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
5	Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
6	Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
7	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.